carfilzomib
Showing 26 - 50 of 159
Long-term KRd in Relapsed and/or Refractory Multiple Myeloma
Not yet recruiting
- Multiple Myeloma in Relapse
- Multiple Myeloma, Refractory
- Carfilzomib
- +2 more
- (no location specified)
Aug 8, 2022
Relapsed or Refractory Multiple Myeloma Trial (Forimtamig, Carfilzomib, Daratumumab)
Not yet recruiting
- Relapsed or Refractory Multiple Myeloma
- Forimtamig
- +2 more
- (no location specified)
Sep 20, 2023
Multiple Myeloma Trial in United States (Carfilzomib, Pomalidomide, Dexamethasone)
Terminated
- Multiple Myeloma
- Carfilzomib
- +2 more
-
Atlanta, Georgia
- +8 more
Jul 28, 2022
Hematologic Malignancies, Relapse, GVHD Trial in Ann Arbor (Carfilzomib, Tacrolimus)
Completed
- Hematologic Malignancies
- +2 more
- Carfilzomib
- Tacrolimus
-
Ann Arbor, MichiganUniversity of Michigan Hospital
Dec 3, 2021
Multiple Myeloma in Relapse Trial in Aurora (Selinexor, Pomalidomide, Daratumumab)
Recruiting
- Multiple Myeloma in Relapse
- Selinexor
- +4 more
-
Aurora, ColoradoUniversity of Colorado Hospital
Jan 31, 2023
Relapsed Solid Tumors, Refractory Solid Tumors, Relapsed Leukemia Trial in Canada, United States (Carfilzomib, Cyclophosphamide,
Recruiting
- Relapsed Solid Tumors
- +3 more
- Carfilzomib
- +2 more
-
Phoenix, Arizona
- +7 more
Apr 12, 2022
Multiple Myeloma Trial in Washington, Hackensack (Selinexor 60 MG, Selinexor 80 MG, Selinexor 100 MG)
Recruiting
- Multiple Myeloma
- Selinexor 60 MG
- +6 more
-
Washington, District of Columbia
- +1 more
Feb 3, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (Carfilzomib, Chemosensitivity Assay,
Terminated
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Carfilzomib
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
May 6, 2022
Smouldering Myeloma Trial in Worldwide (Carfilzomib, Dexamethasone, Lenalidomide)
Recruiting
- Smouldering Myeloma
- Carfilzomib
- +2 more
-
Brno, Czechia
- +15 more
Mar 22, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in United States (drug, biological, other)
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Carfilzomib
- +4 more
-
Des Moines, Iowa
- +8 more
Jan 12, 2023
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (Carfilzomib, Dexamethasone, Pomalidomide)
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Carfilzomib
- +5 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jun 3, 2022
Plasma Cell Myeloma Trial in Atlanta (Carfilzomib, Dexamethasone, Pomalidomide)
Recruiting
- Plasma Cell Myeloma
- Carfilzomib
- +2 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Oct 5, 2021
Multiple Myeloma Trial in United States (Carfilzomib, Lenalidomide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Carfilzomib
- +2 more
-
Basking Ridge, New Jersey
- +5 more
Nov 18, 2021
Contiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Stage I Adult
Completed
- Contiguous Stage II Adult Lymphoblastic Lymphoma
- +5 more
- carfilzomib
- +10 more
-
Sacramento, CaliforniaUniversity of California Davis
Mar 8, 2022
Multiple Myeloma Trial in United States (Carfilzomib, Lenalidomide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Carfilzomib
- +4 more
-
Birmingham, Alabama
- +11 more
Aug 11, 2022
Myeloma, Multiple Myeloma Trial in Chicago (Daratumumab, Carfilzomib, Lenalidomide)
Recruiting
- Myeloma
- Multiple Myeloma
- Daratumumab
- +3 more
-
Chicago, IllinoisThe University of Chicago
Sep 15, 2021
Myeloma Multiple, Myeloma, Plasma-Cell, Myeloma-Multiple Trial in Israel (Carfilzomib, Daratumumab, Lenalidomide)
Completed
- Myeloma Multiple
- +3 more
- Carfilzomib
- +3 more
-
Afula, Israel
- +13 more
Jan 26, 2022
Multiple Myeloma Trial in United States (panobinostat, carfilzomib)
Relapsed/Refractory Multiple Myeloma Trial in Worldwide (BGB-11417, Dexamethasone, Carfilzomib)
Recruiting
- Relapsed/Refractory Multiple Myeloma
- BGB-11417
- +2 more
-
Birmingham, Alabama
- +21 more
Aug 8, 2022
Multiple Myeloma Trial in Canada (Carfilzomib, Cyclophosphamide, Dexamethasone)
Completed
- Multiple Myeloma
- Carfilzomib
- +2 more
-
Edmonton, Alberta, Canada
- +8 more
Feb 1, 2022